LTGO (Latigo Biotherapeutics) EPS (Basic): $ (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTGO Latigo Biotherapeutics Inc LTGO
8 GF Score
Price $18.56
View Full Analysis

What is Latigo Biotherapeutics EPS (Basic)?

Latigo Biotherapeutics LTGO +1.70% 8 EPS (Basic) is $ as of Dec. 2025. GuruFocus rates LTGO with a GF Score™ of 8/100.

Latigo Biotherapeutics's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was $-2.48. Latigo Biotherapeutics does not have enough years/quarters to calculate its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025.

Latigo Biotherapeutics's EPS (Diluted) for the six months ended in Dec. 2025 was $-2.48. Latigo Biotherapeutics does not have enough years/quarters to calculate its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025.

Latigo Biotherapeutics's EPS without NRI for the six months ended in Dec. 2025 was $-2.48. Latigo Biotherapeutics does not have enough years/quarters to calculate its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Latigo Biotherapeutics  (NAS:LTGO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Latigo Biotherapeutics EPS (Basic) Related Terms

Latigo Biotherapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Latigo Biotherapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Latigo Biotherapeutics EPS (Basic) Chart

Latigo Biotherapeutics Annual Data
Trend Dec24 Dec25
EPS (Basic)
-1.39 -2.48

Latigo Biotherapeutics Semi-Annual Data
Dec24 Dec25
EPS (Basic) -1.39 -2.48
LTGO
8GF Score
Latigo Biotherapeutics Inc LTGO
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Latigo Biotherapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Latigo Biotherapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-109.167-0)/43.958
=-2.48

Latigo Biotherapeutics's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-109.167-0)/43.958
=-2.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $ mean?
Latigo Biotherapeutics (LTGO) has a EPS (Basic) of $ as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Latigo Biotherapeutics and its competitors.
Is Latigo Biotherapeutics' EPS (Basic) too high?
Latigo Biotherapeutics' current EPS (Basic) is $. Overall, Latigo Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Latigo Biotherapeutics' EPS (Basic) compare to ?
Latigo Biotherapeutics' EPS (Basic) of $ can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Latigo Biotherapeutics and its competitors. Latigo Biotherapeutics's current EPS (Basic) is $. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Latigo Biotherapeutics stock overvalued right now?
Latigo Biotherapeutics (LTGO) has a current EPS (Basic) of $. The current EPS (Basic) is $. Latigo Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Latigo Biotherapeutics (LTGO), the current EPS (Basic) is $ as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Latigo Biotherapeutics Business Description

Comparable Companies
Address 1300 Rancho Conejo Boulevard, Suite 305, Thousand Oaks, CA, USA, 91320
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
8GF Score

Get the complete analysis for LTGO

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.56
Price